Mittempergher Archives - Agendia

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology
Gallery
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

BluePrint, Evidence, MammaPrint, Other, Validation

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue Read More

kevin2024-03-25T08:36:57-04:00September 1st, 2019|BluePrint, Evidence, MammaPrint, Other, Validation|

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue
Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue

Evidence, MammaPrint, Other, Validation

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue

PUBLICATION: PLoS One. 2011 Feb 11;6(2):e17163. doi: 10.1371/journal.pone.0017163. AUTHORS: Mittempergher Read More

kevin2024-03-07T11:49:23-05:00February 11th, 2011|Evidence, MammaPrint, Other, Validation|

Agendia precision oncology

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients
Newsroom

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.